Aster DM Healthcare quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	1,311	1,078	+21.6%
EBITDA	264	207	+27.5%
EBITDA margin	20.2%	19.2%	+0.9 pts
Profit before tax	86.5	142	−39.2%
Net profit	29.3	93.6	−68.7%
EPS	₹0.31	₹1.67	−81.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	1,311	1,182	1,186	1,197	1,078	1,000	1,050	1,086	1,002	974	3,711	3,317	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	37.0	36.2	28.0	28.3	33.2	31.3	33.0	35.2	48.7	4.1	8.0	8.6
	1,348	1,219	1,214	1,225	1,111	1,032	1,083	1,122	1,051	978	3,719	3,325
	300	259	270	271	247	218	232	245	225	230	1,116	1,052
	−8.6	4.2	−3.0	−0.0	−0.0	7.1	15.0	−7.2	3.3	1.8	−44.6	−92.9
	242	220	221	212	195	183	194	193	190	171	1,162	1,130
	31.2	30.0	31.5	30.8	30.8	32.4	30.8	31.5	29.2	29.9	98.6	102
	69.3	67.2	67.7	66.1	63.2	64.0	62.2	62.3	60.4	58.4	232	227
	512	467	486	464	429	400	420	436	419	412	913	850
	1,147	1,047	1,074	1,044	965	905	954	960	928	902	3,477	3,268
	264	233	211	250	207	192	189	220	164	159	564	377
	195	165	144	184	144	128	127	157	103	101	333	150
Profit
	201	172	140	181	147	127	129	161	123	75.2	242	56.8
	−114	0.3	−28.3	−0.4	−4.4	−26.4	−23.7	0.0	0.0	0.0	0.0	−54.6
	86.5	172	112	181	142	101	105	161	123	75.2	242	2.1
	57.0	36.4	59.1	46.5	44.0	18.0	30.8	46.5	30.4	−16.3	34.7	29.9
	−8.2	−26.6	−14.7	−1.0	−1.1	−13.0	6.7	6.4	8.6	46.9	−10.5	−19.7
	48.8	9.8	44.4	45.5	42.9	5.0	37.5	52.9	39.0	30.6	24.2	10.2
	−8.4	−8.5	−8.8	−14.0	−5.7	−10.0	−3.6	−2.6	−2.7	−2.9	−8.5	−7.3
	29.3	154	58.7	121	93.6	85.5	64.4	106	5,152	−2.2	209	−15.3
	37.7	162	67.4	135	99.3	95.6	68.0	108	83.7	44.6	218	−8.0
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5,071	−43.9	0.0	0.0
	0.1	2.6	−2.1	0.2	−0.4	−2.0	−0.1	−0.1	0.0	21.3	−0.3	28.1
	29.4	156	56.6	122	93.2	83.6	64.3	106	5,152	19.1	209	12.8
	16.1	140	52.5	110	85.5	79.0	56.8	96.8	5,145	−24.0	179	−30.8
	13.2	13.4	6.2	11.3	8.0	6.5	7.6	8.9	7.0	21.9	30.0	15.5
Per share
	₹0.31	₹2.72	₹1.02	₹2.13	₹1.67	₹1.59	₹1.14	₹1.94	₹103.34	−₹0.48	₹3.60	−₹0.62
	₹0.31	₹2.71	₹1.02	₹2.13	₹1.67	₹1.58	₹1.14	₹1.94	₹103.19	−₹0.48	₹3.60	−₹0.62
Continuing & discontinued operations
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5,071	−43.6	0.0	0.0
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0
Other comprehensive income — detail
	0.1	2.6	−2.1	0.2	−0.4	−2.0	—	—	—	—	—	—
	—	2.7	−2.9	—	—	−3.1	—	—	—	13.9	0.0	0.0
	—	0.7	−0.7	—	—	−0.8	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	—	0.0	1.5	0.0	0.0
	0.1	0.7	0.3	0.3	−0.5	0.4	−0.1	−0.1	0.0	5.6	1.7	40.8
	0.0	0.2	0.1	0.1	−0.1	0.1	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	0.0	0.0	−3.3	2.0	12.8
	16.2	143	50.6	110	85.1	77.1	56.7	96.8	5,145	−3.1	179	−6.4
	13.2	13.6	6.0	11.3	8.0	6.5	7.6	8.9	7.0	22.2	30.1	19.2
Per share — as-filed variants
	₹0.31	₹2.72	₹1.02	₹2.13	₹1.67	₹1.59	₹1.14	₹1.94	₹1.49	₹0.66	₹3.60	−₹0.62
	₹0.31	₹2.71	₹1.02	₹2.13	₹1.67	₹1.58	₹1.14	₹1.94	₹1.48	₹0.66	₹3.60	−₹0.62
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹101.85	−₹1.14	₹0.00	₹0.00
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹101.71	−₹1.14	₹0.00	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,019	919	918	926	831	775	803	849	773	742	2,639	2,357
	77.7%	77.7%	77.4%	77.4%	77.1%	77.5%	76.5%	78.1%	77.2%	76.2%	71.1%	71.1%
Adjusted (ex-exceptional items) — derived
	201	172	140	181	147	127	129	161	123	75.2	242	56.8
	−114	0.3	−28.3	−0.4	−4.4	−26.4	−23.7	0.0	0.0	0.0	0.0	−54.6
	79.1	153	75.7	122	96.6	111	79.7	106	5,152	−2.2	209	6.5
	₹0.84	₹2.71	₹1.32	₹2.13	₹1.72	₹2.06	₹1.41	₹1.94	₹103.34	−₹0.48	₹3.60	₹0.26

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ASTERDM₹679.20

Aster DM Healthcare Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAPOLLOHOSP MAXHEALTH KIMS COHANCE WOCKPHARMA SYNGENE GLAND LALPATHLABMcap ₹35,191 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	3,316.6	3,710.6	973.6	1,001.9	1,086.4	1,049.8	1,000.3	1,077.9	1,197.2	1,185.8	1,182.4	1,310.7
Other Income	8.6	8.0	4.1	48.7	35.2	33.0	31.3	33.2	28.3	28.0	36.2	37.0
Total Income	3,325.2	3,718.6	977.7	1,050.6	1,121.7	1,082.8	1,031.6	1,111.1	1,225.5	1,213.7	1,218.6	1,347.7
Expenses
+ Purchases of Stock-in-Trade	1,052.1	1,116.3	230.0	225.3	244.7	232.0	218.2	247.2	271.1	270.4	259.0	300.4
+ Changes in Inventories	-92.9	-44.6	1.8	3.3	-7.2	15.0	7.1	-0.0	-0.0	-3.0	4.2	-8.6
+ Employee Benefit Expense	1,129.9	1,162.2	170.9	190.4	193.4	193.6	183.0	194.8	211.9	221.4	220.0	242.2
+ Finance Costs	101.9	98.6	29.9	29.2	31.5	30.8	32.4	30.8	30.8	31.5	30.0	31.2
+ Depreciation & Amortisation	227.2	231.5	58.4	60.4	62.3	62.2	64.0	63.2	66.1	67.7	67.2	69.3
+ Other Expenses	850.3	912.5	411.6	419.3	435.9	420.0	400.1	428.6	464.4	485.7	466.7	512.4
Total Expenses	3,268.5	3,476.7	902.5	927.9	960.4	953.6	904.7	964.5	1,044.3	1,073.6	1,047.0	1,146.9
EBITDA	377.3	564.1	159.3	163.5	219.7	189.2	192.1	207.4	249.8	211.3	232.6	264.3
EBIT	150.1	332.6	101.0	103.1	157.5	127.0	128.1	144.1	183.7	143.6	165.3	195.0
Profit
PBT before Exceptional Items	56.8	241.9	75.2	122.7	161.3	129.2	127.0	146.6	181.2	140.1	171.6	200.9
+ Exceptional Items	-54.6	0.0	0.0	0.0	0.0	-23.7	-26.4	-4.4	-0.4	-28.3	0.3	-114.4
Pretax Income	2.1	241.9	75.2	122.7	161.3	105.5	100.6	142.2	180.9	111.8	171.9	86.5
+ Current Tax	29.9	34.7	-16.3	30.4	46.5	30.8	18.0	44.0	46.5	59.1	36.4	57.0
+ Deferred Tax	-19.7	-10.5	46.9	8.6	6.4	6.7	-13.0	-1.1	-1.0	-14.7	-26.6	-8.2
Tax Expense	10.2	24.2	30.6	39.0	52.9	37.5	5.0	42.9	45.5	44.4	9.8	48.8
+ Share of Associates & JVs	-7.3	-8.5	-2.9	-2.7	-2.6	-3.6	-10.0	-5.7	-14.0	-8.8	-8.5	-8.4
Net Income	-15.3	209.2	-2.2	5,152.2	105.8	64.4	85.5	93.6	121.3	58.7	153.6	29.3
+ Net Income — Continuing Ops	-8.0	217.7	44.6	83.7	108.4	68.0	95.6	99.3	135.3	67.4	162.1	37.7
+ Net Income — Discontinued Ops	0.0	0.0	-43.9	5,071.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Other Comprehensive Income	28.1	-0.3	21.3	0.0	-0.1	-0.1	-2.0	-0.4	0.2	-2.1	2.6	0.1
Total Comprehensive Income	12.8	209.0	19.1	5,152.2	105.7	64.3	83.6	93.2	121.5	56.6	156.2	29.4
Net Income to Common	-30.8	179.2	-24.0	5,145.2	96.8	56.8	79.0	85.5	110.0	52.5	140.2	16.1
Minority Interest	15.5	30.0	21.9	7.0	8.9	7.6	6.5	8.0	11.3	6.2	13.4	13.2
Per Share
Basic EPS	-0.62	3.60	-0.48	103.34	1.94	1.14	1.59	1.67	2.13	1.02	2.72	0.31
Diluted EPS	-0.62	3.60	-0.48	103.19	1.94	1.14	1.58	1.67	2.13	1.02	2.71	0.31
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	0.0	-43.6	5,071.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Tax — Discontinued Operations	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-2.0	-0.4	0.2	-2.1	2.6	0.1
+ Items NOT to be Reclassified to P&L	0.0	0.0	13.9	—	—	—	-3.1	—	—	-2.9	2.7	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.8	—	—	-0.7	0.7	—
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.0	1.5	0.0	—	0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	40.8	1.7	5.6	0.0	-0.1	-0.1	0.4	-0.5	0.3	0.3	0.7	0.1
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.1	-0.1	0.1	0.1	0.2	0.0
+ Tax on Items to be Reclassified — alt tag	12.8	2.0	-3.3	0.0	0.0	0.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	-6.4	178.9	-3.1	5,145.2	96.8	56.7	77.1	85.1	110.2	50.6	142.6	16.2
Comprehensive Income — Non-controlling Interests	19.2	30.1	22.2	7.0	8.9	7.6	6.5	8.0	11.3	6.0	13.6	13.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	-0.62	3.60	0.66	1.49	1.94	1.14	1.59	1.67	2.13	1.02	2.72	0.31
Diluted EPS — Continuing Operations	-0.62	3.60	0.66	1.48	1.94	1.14	1.58	1.67	2.13	1.02	2.71	0.31
Basic EPS — Discontinued Operations	0.00	0.00	-1.14	101.85	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	0.00	0.00	-1.14	101.71	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,357.4	2,638.9	741.8	773.3	849.0	802.8	775.1	830.7	926.2	918.3	919.2	1,018.9
Gross Margin %	71.08	71.12	76.19	77.18	78.14	76.47	77.48	77.07	77.36	77.44	77.74	77.74
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	56.8	241.9	75.2	122.7	161.3	129.2	127.0	146.6	181.2	140.1	171.6	200.9
− Exceptional Items (reconciliation)	-54.6	0.0	0.0	0.0	0.0	-23.7	-26.4	-4.4	-0.4	-28.3	0.3	-114.4
Net Income Adj (tax-effected)	6.5	209.2	-2.2	5,152.2	105.8	79.7	110.6	96.6	121.6	75.7	153.3	79.1
EPS Adj	0.26	3.60	-0.48	103.34	1.94	1.41	2.06	1.72	2.13	1.32	2.71	0.84
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	499.5	499.5	499.5	499.5	499.5	499.5	499.5	518.1	518.1	518.1	518.1	518.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Aster DM Healthcare Q2 FY27 results date

Aster DM Healthcare (NSE: ASTERDM) will announce its Q2 FY27 results (July–September 2026) on Friday, 6 November 2026, according to the board-meeting notice it filed on 28 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹16.1 crore, down 81.2% from ₹85.5 crore in Q1 FY26 and down 88.5% from ₹140 crore in Q4 FY26. Revenue from operations was ₹1,311 crore, up 21.6% year on year and up 10.9% from the previous quarter.

Board-meeting notice filed: 28 October 2026
Q2 FY26 results (a year earlier): 6 November 2025
Q1 FY27 results (the latest): 5 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 6 November 2026Friday · notice filed 28 Oct
Q1 FY27 net profit: ₹16.1 Cr−81.2% vs Q1 FY26−88.5% vs Q4 FY26
Q1 FY27 revenue: ₹1,311 Cr+21.6% vs Q1 FY26+10.9% vs Q4 FY26
Q1 FY27 operating margin: 14.9%+1.5 pts vs Q1 FY26+0.9 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹110 CrRevenue ₹1,197 Cr
Q1 FY27 EPS (basic): ₹0.31

Questions

When will Aster DM Healthcare announce its Q2 FY27 results?

On 6 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 28 October 2026). Last year it reported Q2 FY26 on 6 November 2025.

What will Aster DM Healthcare's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹110 crore and revenue from operations ₹1,197 crore. The latest quarter, Q1 FY27, had a net profit of ₹16.1 crore and revenue of ₹1,311 crore.

What were Aster DM Healthcare's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹16.1 crore, down 81.2% from ₹85.5 crore in Q1 FY26 and down 88.5% from ₹140 crore in Q4 FY26. Revenue from operations was ₹1,311 crore, up 21.6% year on year and up 10.9% from the previous quarter.

How has Aster DM Healthcare's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹110 crore in Q2 FY26, ₹52.5 crore in Q3 FY26, ₹140 crore in Q4 FY26 and ₹16.1 crore in Q1 FY27. That is ₹319 crore over the four quarters, up 0.2% from ₹318 crore in the four quarters before. Revenue from operations: ₹1,197 crore, ₹1,186 crore, ₹1,182 crore and ₹1,311 crore.

What was Aster DM Healthcare's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹388 crore in FY26 (April 2025–March 2026), down 92.8% from ₹5,378 crore in FY25. It was ₹129 crore in FY24 and ₹425 crore in FY23: down 8.7% over three years, an average fall of 3.0% a year.

What was Aster DM Healthcare's revenue in FY26?

Revenue from operations was ₹4,643 crore in FY26 (April 2025–March 2026), up 12.2% from ₹4,138 crore in FY25. It was ₹3,699 crore in FY24 and ₹11,933 crore in FY23: down 61.1% over three years, an average fall of 27.0% a year.

Where do these Aster DM Healthcare figures come from?

From Aster DM Healthcare's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.